A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL)
NCT ID: NCT06834789
Last Updated: 2025-11-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
132 participants
INTERVENTIONAL
2025-02-18
2025-11-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Assess Adverse Events of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines
NCT05248893
A Study to Evaluate AGN-151586 Intramuscular Injections in Adult Participants for Treatment of Glabellar Lines
NCT06308198
AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines
NCT04096326
Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Glabellar Lines
NCT03736928
MT10109L in the Treatment of Glabellar Lines
NCT03795922
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1: AGN-151586 Dose A and OnabotulinumtoxinA
Participants will receive a single treatment of AGN-151586 Dose A and OnabotulinumtoxinA.
AGN-151586
Intramuscular injection
OnabotulinumtoxinA
Intramuscular injection
Cohort 2: AGN-151586 Dose B and OnabotulinumtoxinA
Participants will receive a single treatment of AGN-151586 Dose B and OnabotulinumtoxinA.
AGN-151586
Intramuscular injection
OnabotulinumtoxinA
Intramuscular injection
Cohort 3: AGN-151586 Dose A and OnabotulinumtoxinA
Participants will receive a single treatment of AGN-151586 Dose A and OnabotulinumtoxinA.
AGN-151586
Intramuscular injection
OnabotulinumtoxinA
Intramuscular injection
Cohort 3: AGN-151586 Dose B and OnabotulinumtoxinA
Participants will receive a single treatment of AGN-151586 Dose B and OnabotulinumtoxinA.
AGN-151586
Intramuscular injection
OnabotulinumtoxinA
Intramuscular injection
Cohort 3: Placebo and OnabotulinumtoxinA
Participants will receive a single treatment of Placebo and OnabotulinumtoxinA.
OnabotulinumtoxinA
Intramuscular injection
Placebo
Intramuscular injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AGN-151586
Intramuscular injection
OnabotulinumtoxinA
Intramuscular injection
Placebo
Intramuscular injection
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Must be in good health as per investigator's judgment based on medical history, physical examination, vital sign measurements, 12-lead ECG parameters, clinical laboratory evaluations, and neurological assessment.
Exclusion Criteria
* History of immunization to any botulinum neurotoxin serotype or hypersensitivity to any botulinum neurotoxin serotype or any other constituents of the study drug or its excipients, and/or other products in the same class.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AbbVie
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
ABBVIE INC.
Role: STUDY_DIRECTOR
AbbVie
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Investigate MD /ID# 270771
Scottsdale, Arizona, United States
Eye Research Foundation /ID# 270827
Newport Beach, California, United States
Marcus Facial Plastic Surgery /ID# 270770
Redondo Beach, California, United States
Skin Research Institute LLC /ID# 270831
Coral Gables, Florida, United States
Skincare Physicians /ID# 271018
Chestnut Hill, Massachusetts, United States
Wilmington Dermatology Center /ID# 270828
Wilmington, North Carolina, United States
Austin Institute for Clinical Research - Pflugerville /ID# 270834
Pflugerville, Texas, United States
SkinDC /ID# 270932
Arlington, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
M25-207
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.